Zobrazeno 1 - 10
of 281
pro vyhledávání: '"F, De Vassal"'
Autor:
E. d’Hubert, J-L. Misset, F. Kemeny, M. Musset, F. de Vassal, M-A. de Maublanc, R. Hagipantelli, S. Brienza, Mathé G, F. Burki, R. Despax, M. Itzhaki, C. Regensberg
Publikováno v:
Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy ISBN: 9782817807843
One hundred and eleven patients presenting a breast cancer were treated with intensive and prolonged chemotherapy from 1980 to 1990. Medium age is 50, 2 patients have less than 20 and 5 more than 70. All fulfill selection criteria: no countra-indicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b3ae3f2f127e52c5633a5984321425a
https://doi.org/10.1007/978-2-8178-0782-9_36
https://doi.org/10.1007/978-2-8178-0782-9_36
Autor:
M. Delgado, Misset Jl, A. Cattan, C. Jasmin, C. Rosenfeld, D. Belpomme, Musset M, Schwarzenberg L, Ribaud P, M. A. Gil, Jean-Louis Amiel, P. Pouillart, Jose-Luis Pico, F. de Vassal, Schneider M, M. Hayat, Georges Mathé, Pena-Angulo J, Machover D, R. Weiner
Publikováno v:
Medical and Pediatric Oncology. 4:17-27
Autor:
Mathé G, Pierre Pouillart, Jeanne Amiel, Jasmin C, F. de Vassal, M. Hayat, Schwarzenberg L, Rosenfeld C
Publikováno v:
Proceedings of the Royal Society of Medicine. 68:211-216
The present results of our treatment of acute lymphoid leukaemia patients are summarized: 7 out of 20 randomized patients given active immunotherapy after chemoradiotherapy are still in complete remission after periods varying from seven to ten years
Autor:
M. Musset, Jeanne Amiel, M. Hayat, Schwarzenberg L, J.L. Misset, D. Machover, A. Cattan, J. Pena-Angulo, M. Delgado, Rosenfeld C, M. A. Gil, Mathé G, Pierre Pouillart, R. Weiner, Jose-Luis Pico, Jasmin C, F. de Vassal, Schneider M, Belpomme D
Publikováno v:
Cancer Immunology, Immunotherapy. 2:225-232
Publikováno v:
European Journal of Cancer (1965). 13:445-455
Active immunotherapy (A.I.) has given 85% cure expectancy to patients of all ages suffering from acute lymphoid types of leukemia called "microlymphoblastic". Cure expectancy for those with the prolymphocytic or macrolymphoblastic types is 40–50% .
Autor:
M. Hayat, Jasmin C, M. Delgado, Pierre Pouillart, Maurice Tubiana, D. Machover, M. Musset, C. Tentas, B. Caillou, Schwarzenberg L, J.L. Misset, F. de Vassal, M. A. Gil, Patricia Ribaud, Georges Mathé
Publikováno v:
Cancer Chemotherapy and Pharmacology. 1:197-202
We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementar
Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas
Autor:
M. Musset, Jose-Luis Pico, D. Machover, Belpomme D, Jasmin C, Patricia Ribaud, L M De Luca, Schwarzenberg L, F. de Vassal, J.L. Misset, Mathé G, M. Bayssas, M. Hayat, J. Gouveia
Publikováno v:
Cancer Chemotherapy and Pharmacology. 2:247-255
Vindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proport
Autor:
Schneider M, Jasmin C, Rosenfeld C, Jeanne Amiel, A. Cattan, J. R. Schlumberger, F. de Vassal, Schwarzenberg L, Mathé G, M. Hayat
Publikováno v:
BMJ. 1:836-839
The results obtained during the first three years of a pathogen-free isolation unit containing five beds have shown that this type of unit can reduce the risk of infection in patients treated with intensive chemotherapy or in those who have granulocy
Autor:
V, Georgoulias, J L, Misset, P, Ribaud, D, Machover, F, De Vassal, T, Dorval, M, Musset, L, Schwarzenberg, P, Reizenstein, G, Mathe, H, Gaget
Publikováno v:
Anticancer research. 3(2)
Thirty-nine evaluable patients with squamous cell lung carcinoma were treated with combination chemotherapy consisting of doxorubicin, oncovin, bleomycin, cytembena and cis-platin. Objective responses were seen in 46 per cent of the patients. Patient